REGN News and Press, Regeneron Pharmaceuticals Inc. From 02/24/26

2026-02-24 10:32:21 ET More on Regeneron Pharmaceuticals Regeneron: Expect Double-Digit Growth In 2026 Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Regen...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by...

2026-02-23 22:35:52 ET Company Background Electromed ( ELMD ) is a small medical device company based in Minnesota. It was founded in 1992 by Robert D. Hansen and Craig N. Hansen, and it IPO’d in 2010 at $4 a share. Shareholders did pretty poorly in the first 9 years ...

2026-02-19 07:31:05 ET More on Regeneron Pharmaceuticals Regeneron: Expect Double-Digit Growth In 2026 Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Regen...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  If approved, garetosmab would be the first and only available treatment shown to reduce the numbe...

2026-02-17 13:37:15 ET The last time I spoke about Ocular Therapeutix ( OCUL ) was regarding a Seeking Alpha article entitled " Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement ." I noted that the company was in the process of advancing its drug in sever...

2026-02-17 08:25:08 ET More on Ocular Therapeutix Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix Ocular...

2026-02-13 05:45:00 ET The following segment was excerpted from the Baird International And Global Growth Funds Q4 2025 Commentary And Market Outlook. ... Read the full article on Seeking Alpha For further details see: Baird Chautauqua In...

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent ® (dupilumab) data highlight its clinical and real-world impact acros...

2026-02-05 15:07:58 ET Image source: The Motley Fool. Tuesday, April 29, 2025 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading